`Institut Universitaire d`Hématologie

Les Instituts Hospitalo-Universitaires, Concevoir
les thérapies du futur
• Les instituts hospitalo-universitaires sont une création émanant du
programme « Santé et biotechnologies » des investissements
d'avenir (Grand emprunt 2010).
• Créés autour des pôles d’excellence hospitalo-universitaires, ils ont
vocation à stimuler la recherche biomédicale dans des secteurs
porteurs, à assurer la promotion d’innovations et à faciliter leur
exploitation dans le cadre de partenariats industriels jusqu’à leurs
transferts dans la pratique de soins.
• Ces programmes ambitieux visent à accroître la compétitivité de la
France et à permettre aux patients de bénéficier le plus tôt possible
des avancées thérapeutiques.
a world class hospital for
personalized Hematology
… in conjunction with Denis Diderot Medical Faculty
FACULTE DE MEDECINE PARIS DIDEROT
a leading institute
for medical research and training,
at University Paris Diderot
Clinical Partner: The Saint-Louis Hospital
(150 Beds for hematology – 110 ME/yr)
First hospital in France:
•
•
Hematopoietic stem cell transplantation
Number of patients treated for
•
acute leukemias
•
lymphomas
•
myeloma
(source DPM AP-HP)
Research and Education Partner: The « Institut
Universitaire d'Hematologie »
www.univ-paris-diderot.fr/IUH/
« Institut Universitaire d'Hematologie »
« First » worldwide
Jean Bernard: demonstration that leukemias are
cancers and first remission in leukemias
Jean Dausset: the HLA system (Nobel Prize 1980)
Eliane Gluckman: Cord Blood Transplantation
(Honour Prize, INSERM 2011)
Laurent Degos: first targeted therapy in cancer
(General Motor Prize)
« Institut Universitaire d'Hematologie »
Teaching and Education
The PhD School ‘Biology and Biotechnology’ of Paris Diderot
and Paris Descartes Universities (Pr. Sigaux)
The international School for continuous education, the
European School of Hematology (www.esh.org)(Pr. Gluckman)
Main research areas of
‘Institut Universitaire d’Hématologie ’
Molecular and functional characterization of neoplastic
blood disorders and solid tumours
Focus:
Multiparametric profiling of tumors
Characterization of leukemic and tumour stem cells
In vitro and in vivo characterization of the function of
genes involved in carcinogenesis
Modelling tumors in mice (transgenics and xenografts)
Tumor Genetics (with the CEPH)
Transplantation, cell therapy, gene therapy
Focus:
Virology
Focus:
Histocompatibility
Hemopoietic stem cell transplantation
GVH
Interactions between virus and cells
Phamacology
Focus:
Cell biology, molecular virology and modulation of apoptosis,
differentiation and cell cycle
Therapeutic manipulation of host-tumour relationships:
angiogenesis, tumour stem cells, immune responses
Biostatistics of therapeutic trials
Focus
Methodology of phase I trials
Design, conduct and analysis of trials
in neoplastic blood disorders
« Institut Universitaire d'Hematologie »
First Hematology Research Center in France
Budget:28 ME
Number of Pi:135 , total members:430
12000 m2 for research, technology and teaching
« Institut Universitaire d'Hematologie »
‘Institut Universitaire d’Hématologie ’
International cooperations
Le Centre Meary
• Complète l’offre du campus de l’Hôpital Saint-Louis, riche
de ses départements académiques de recherche
fondamentale translationnelle et clinique, hôpital
français de référence en Hématologie et greffes de
cellules hématopoïétiques.
• Dédié à la recherche partenariale et au
développement, troisième volet du triptyque
plaçant la recherche partenariale et l’innovation
thérapeutique dans un continuum de
développement avec la recherche académique
et le soin.
Réunion Meary
Jeudi 5 juin 2014
Hôpital
Saint-Louis
AP-HP
IUH
1/ L’hypothèse
scientifique
Ressources biologiques
Cohortes
CIC
3/L’essai clinique
Centre Meary
2/La preuve du concept
et
Le développement
Partenaires
Industriels
Bio-marqueurs
Médicaments
Thérapie cellulaire
Le Centre Meary
CENTRE DE FORMATION ET
DE RECHERCHES
TRANSLATIONNELLES EN
HEMATO-ONCOLOGIE
Objectif : mettre en place les
infrastructures et plateformes
nécessaires à une recherche
capable de se positionner au
meilleur niveau mondial, pour
accéder rapidement à une
médecine plus personnalisée
Réunion Meary
Jeudi 5 juin 2014
Le Centre Meary
• Un projet stratégique (plan stratégique 2010-2014 de l’AP-HP), dispositif
majeur du projet SLI
• Un jalon supplémentaire pour renforcer la spécialisation historique en
hémato-oncologie de l’hôpital Saint-Louis
• Un centre dédié à l’innovation et à l’interface publique-privée : étroitement
associé à la recherche fondamentale, translationnelle ou clinique et aux
soins dispensés à l’hôpital, il permettra aux entreprises privées consacrées à
la recherche médicale de trouver l’environnement optimal pour mener à
bien leurs travaux.
• Saint-Louis constituera ainsi un des trois ou quatre centres de niveau
mondial en recherche clinique et pour le soin en hémato-oncologie.
Réunion Meary
Jeudi 5 juin 2014
Meary, le concept
Onco-Hémato
Focus biomarqueurs
Médecine de précision
Idée
Public
Médecins
Ingénieurs
Privé
Chercheurs
Médicament et dispositifs médicaux
FORMATION
Réunion Meary
Jeudi 5 juin 2014
Meary, 3 dimensions
Formation
Réunion Meary
Jeudi 5 juin 2014
Laboratoires
Plateformes
Meary, 4 piliers
Réunion Meary
Jeudi 5 juin 2014
Ressources
bio
OMICS
Info/bioinfo
Thérapie
cellulaire
Le bâtiment Meary en résumé
•
•
•
•
Construit sur la dalle Méary de l’Hôpital Saint-Louis.
Rénovation complète de l’entresol (850 m² environ) de la « dalle MEARY » ainsi que la
construction de deux niveaux supplémentaires de 1 000m² chacun,
Surface totale de 2 850 m², recouvert d’une toiture terrasse végétalisée destinée à créer
une continuité avec le jardin mitoyen.
Le bâtiment abritera notamment :
– Un auditorium de 120 places et son environnement d’espaces de convivialité
– Un ensemble de plateformes à très haut débit de grade industriel
– Un centre de ressources biologiques annotées adapté aux grandes cohortes
– Un centre serveur
– Des laboratoires d’interface public-privé notamment pour le co-développement de
nouveaux dispositifs médicaux et médicaments ciblés
– Une salle de formation pour « l’Ecole de l’Innovation »
– Une plateforme production de Médicaments Thérapie Innovante
Réunion Meary
Jeudi 5 juin 2014
Université
Paris-Diderot
recherche
fondamentale
Fondation
partenariale
Saint-Louis
recherche
translationnelle
recherche clinique
Institut Universitaire
d’Hématologie
Centre Meary
Pole d’hématologie
Immunologie,
Cancerologie
Hôpital
Saint-Louis
AP-HP
Paris Alliance of
Cancer Research Institutes
Oncology in the „Grand Paris“
Strengths
 A comprehensive set of scientific and medical ressources
 cancer health care for ~17 million people
 600 medical oncologists, 1800 other physicians
 3600 scientists (including post-docs, PhD students)
 Research budget (excluding trials) ~230 Meuros/yr
 Strong involvement in medical innovation
 more than 60% of French high-impact factor publications
 Excellence in basic, translational and clinical research
 more than 40% of French clinical trials in oncology
 Good Ecosystem
 large number of SMEs in biotechnology and several Pharmas.
 good Universities and « Grandes Ecoles »
Oncology in the „Grand Paris“
Weaknesses
 Scattering of ressources and geographical dispersion of clinical and research centers
 Competing Institutions
 Suboptimal translational perspectives and low level of industrial collaborations
 Suboptimal integration of cancer research facilities and biological resources
Oncology in the „Grand Paris“
Opportunities
 2011: new strategic programs for regional networks in research and innovation
 the “Canceropôle Ile de France”
 the “Medicen Cluster”
 2011: the Grand Emprunt (the Big Loan)
 a special action of the French Government designed to reinvigorate
the National research system
 none of the six “IHU” laureates dealt with cancer, but both Gustave Roussy Institute
and St. Louis Institute were classified in positions 7 and 8 of the Nation-wide competition :
merging of both projects was suggested by the International Committee
 The Government decided to launch a new call for proposals dedicated to Oncology
The PACRI Project
Governmental Constraints
 No overlap with existing programs financed by the Big Loan or INCa
 a lot of successful applications: LabeX, EquipeX “promising IHU”, SIRIC etc…
 Low Budget (seeding money) but requirement of a major leverage effect
The PACRI Project
Method: setting an ad-hoc program committee
 Directors (Presidents) and scientific directors of the three major cancer institutes
and of AP-HP (Paris Public Hospitals)
 To decide :Go /no Go
 To define/nominate:
 the objectives “federating, strengthening and increasing the efficiency and visibility
of Cancer research in the Paris area”
 breakthrough questions, for which PACRI claims a number of internationally
recognized experts
 the partners of the project
 the Director of the program
The PACRI Project
PACRI objectives “federating, strengthening and increasing the efficiency and visibility
of Cancer research in the Paris area”
 to promote trans-institutional research networks
 particularly in the fields of molecular genetics, cell biology (integrated Omics:
genomics/proteomics/metabolomics/systems biology), mouse models relevant to
human cancers, preclinical studies, as well as immune exploration, focusing on
practical, therapy-relevant aspects.
 to organize a series of shared technological platforms
including bioinformatics, screening through cell biology imaging or immune
cellular interactions…
 and “mouse clinics” dedicated to production of xenograft or genetically defined
models of tumors and efficient exploration of therapeutic interventions, notably
with approved drugs or those under development.
 to create an integrated educational system
for recruiting, training and tutoring the next generation of cancer researchers and
clinical oncologists
The PACRI Project
breakthrough questions
 Can we approach the genetic and epigenetic heterogeneity of cancers and their
evolution after treatment by novel technologies and mathematical models?
 Could tumors constitute a metabolic micro-ecosystem - notably in the
interactions between cancer and stromal cells - that explains therapy resistance?
 Could conventional (or targeted) therapies induce an anticancer immune
response and is this implicated in their clinical efficacy? Can we design efficient
strategies combining immunotherapies with conventional or targeted therapies in
preclinical models?
 Can we construct in vitro or animal models that more accurately reflect the
growth of human cancers in patients? How can these be conveniently used to assess
anticancer drugs?
PACRI program
 stimulate the exploration of selected breakthrough concepts designed to treat
cancer
 create a “mouse cancer clinics” designed to monitor drug effects on both
xenotransplanted primary human cancers and genetically defined, oncogenedriven murine cancers
 offer a dual service to industrial partners:
* a framework for the preclinical evaluation of drugs
* an improved technology for monitoring innovative clinical trials
under the guidance of the PACRI faculty
 streamline and unify the education of graduate and postgraduate students,
the formation of clinical oncologists, organize foreign exchanges at the
highest international standards and boost clinical and societal integration.
PACRI breakthrough questions
Breakthrough questions
Science &
technology
Education
& training
Technology
platforms
Excellence
Clinical and
industrial impact
Preclinical & clinical
drug development
Architecture of the PACRI Project
I. Innovation
WP1: Heterogeneity
WP2: Function
II. Platforms
WP3: Immunology
WP4: Models
III. Integration
WP5: Platforms
WP6: Integration
IV. Education
WP7: Education
Research Institutes & Hospitals
Research
Institutes
Hospitals
« CLCC »
Saint Louis
Cochin
HEGP
Beaujon
Research budget ~230 Meuros/yr
PACRI Partners
National Research/
Education Institutions
Universities
National Associations
Local/regional
Institutions
Private Partners
PACRI strategy: elitism
The PACRI Faculty: 25 top scientists and
The PACRI Director: Guido Kroemer
clinicians-scientists working in its founding
institutions
PACRI Public Private Partnerships
and Medicen concerted actions
Resources sharing
IP managment
Annotated Bioressources
Carnot Institute
Patient cohorts
IGR&D
Cellular and animal
models
SPC SATT
Advanced proof of
concept
Villejuif building
Maturation processes
Paris Meary building
Research and
development
PP platforms and labs.
Biotech. and
Pharma.
Companies